Medical Device Network on MSN
Synchrony Medical bolsters US COPD treatment commercialisation with $5m funding round
Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.
Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...
Inhaled maintenance therapy is underused among hospitalized patients with COPD in China, even in those with frequent prior hospitalizations.
In patients with COPD and atrial fibrillation or flutter, vitamin K antagonists carry a lower 1‑year risk for hospitalization ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 2026 GOLD report newly highlights disease activity ...
Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...
ABP Live Doc Talk: Most of the patients come into the clinic with complaints of asthma, particularly when they have chronic ...
Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results